Praxis Precision Medicines, Inc. — 2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. This is an annual report, not a standalone fourth-quarter report. Praxis is a clinical-stage biopharmaceutical company developing CNS therapies; it reported no product revenue.
Financial overview
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $45.0 million | $29.6 million |
| General and administrative expense | $17.0 million | $6.2 million |
| Total operating expenses | $62.0 million | $35.8 million |
| Net loss | $61.8 million | $35.5 million |
| Net loss attributable to common stockholders | $70.3 million | $40.7 million |
| Net loss per share, basic and diluted | $7.86 | $26.60 |
| Net cash used in operating activities | $52.6 million | $33.4 million |
| Cash and cash equivalents at year-end | $296.6 million | $44.8 million |
Margins are not meaningful because the company had no revenue. At December 31, 2020, total assets were $303.2 million, total liabilities were $15.7 million, and stockholders’ equity was $287.5 million. The filing reports no borrowings or off-balance-sheet arrangements. Current liabilities included $4.1 million of accounts payable, $10.9 million of accrued expenses and $0.8 million of lease liabilities.
Cash and cash equivalents plus restricted cash totaled $297.2 million. Financing activities provided $304.4 million in 2020, primarily from the IPO and preferred-stock issuances, partly offset by a $30.0 million preferred-stock repurchase. Management estimated available cash would fund operations into the fourth quarter of 2022; it cautioned that this estimate depends on assumptions and that additional capital will be needed to support longer-term plans.
Material changes and notable items
- Net loss increased $26.3 million year over year. R&D expense rose $15.4 million, mainly from higher personnel costs and PRAX-114 clinical spending; G&A rose $10.8 million, reflecting headcount, public-company costs and professional fees.
- Praxis completed its October 2020 IPO, raising approximately $200.3 million net. All outstanding preferred shares converted into common stock at the IPO closing. The company also issued Series C and C-1 preferred stock earlier in 2020 and repurchased $30.0 million of Series C preferred stock.
- Common-stockholder loss exceeded net loss because of $9.0 million in preferred-stock accretion and cumulative dividends, partly offset by a $0.5 million gain on preferred-stock repurchase.
- G&A included approximately $2.1 million of stock-based compensation related to a former employee’s option modification. Total stock-based compensation expense was $5.2 million, versus $0.7 million in 2019.
Business outlook, commentary and risks
- PRAX-114: In an open-label Phase 2a MDD study, the company reported improvements in depression scores within two weeks; the study was small and not placebo-controlled. The FDA placed its U.S. IND on full clinical hold in late 2020 over nonclinical matters, then removed the hold in March 2021 after additional submissions. The company planned to start a Phase 2/3 monotherapy MDD trial by the end of March 2021, with topline results expected in the first half of 2022, and a dose-finding adjunctive MDD trial in the third quarter of 2021. PMD topline data were expected in the second half of 2021.
- PRAX-944: The company cited preliminary tremor reductions in six participants in a small, open-label Phase 2a cohort. It planned to report high-dose cohort data around mid-2021 and start a Phase 2b controlled trial in late 2021. These preliminary findings are not confirmatory efficacy results.
- PRAX-562: The Phase 1 single-ascending-dose portion was complete without dose-limiting toxicities; multiple-dose testing was ongoing. A proof-of-concept study in rare adult headache disorders was planned for the second half of 2021. FDA rare pediatric disease designation had been granted for specified SCN2A- and SCN8A-related disorders.
- Praxis expects continuing operating losses and substantial R&D spending; it has no approved products and has not generated product revenue. Its ability to fund development beyond its cash runway depends on future capital, collaboration or licensing arrangements.
- Key risks include clinical-trial failure or delays, side effects, regulatory uncertainty, competition, reliance on third-party manufacturers and research partners, intellectual-property challenges, reimbursement uncertainty and COVID-19-related disruption. The company disclosed a May 2020 cease-and-desist letter from Sage Therapeutics alleging misuse of confidential information related to PRAX-114; Praxis disputed the allegations. The filing reported no material legal proceedings pending.
Important facts for investors to verify
- Current cash runway and subsequent financing needs relative to the company’s estimate of funding into Q4 2022.
- Final, controlled clinical results for PRAX-114 and PRAX-944, including safety, durability and whether preliminary open-label findings are replicated.
- Progress on PRAX-562’s multiple-dose study and planned patient trials, plus the status of nonclinical and regulatory requirements for each program.
- Potential financial or operational consequences of the Sage allegations, licensing obligations and reliance on third-party manufacturers and collaborators.
- Share dilution from outstanding options and future equity financing; the filing reported 5.9 million options outstanding at year-end 2020.